Amanda F. Gilkes

Heath Park
Cardiff, WLS, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications

Mutational Signatures and Machine Learning for Risk Stratification of Acute Myeloid Leukaemia Based on Targeted Sequencing Data.

Mutational Signatures and Machine Learning for Risk Stratification of Acute Myeloid Leukaemia Based on Targeted Sequencing Data.

Journal: Cancers
Published: April 26, 2026

Expression of RUNX1::RUNX1T1 deregulates the proteome, induces C/EBPβ suppression, and blocks myeloid differentiation.

Expression of RUNX1::RUNX1T1 deregulates the proteome, induces C/EBPβ suppression, and blocks myeloid differentiation.

Journal: Blood neoplasia
Published: January 20, 2026

Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial.

Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial.

Journal: Blood
Published: December 05, 2025

Correction: Kingshott et al. Alteration of Metabolic Conditions Impacts the Regulation of IGF-II/H19 Imprinting Status in Prostate Cancer. Cancers 2021, 13, 825.

Correction: Kingshott et al. Alteration of Metabolic Conditions Impacts the Regulation of IGF-II/H19 Imprinting Status in Prostate Cancer. Cancers 2021, 13, 825.

Journal: Cancers
Published: December 04, 2025

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.

Journal: Blood
Published: August 19, 2025

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Journal: Blood
Published: August 19, 2025

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.

Journal: Blood
Published: July 28, 2025

CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.

CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.

Journal: Blood
Published: July 28, 2025

Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.

Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.

Journal: Blood advances
Published: May 23, 2025

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.

Journal: Blood
Published: April 18, 2025

Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival.

Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival.

Journal: Leukemia
Published: February 07, 2025

A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRDneg remission after intensive induction.

A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRDneg remission after intensive induction.

Journal: HemaSphere
Published: February 02, 2025
Showing 1-12 of 48

Last Updated: 09/26/2026